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The beta-adrenoceptor blocking agents are now
in wide use for the treatment of a variety of cardio-
vascular diseases. They are among the most popu-
lar forms of pharmacologic therapy for the manage-
ment of high blood pressure states and are also used
commonly for angina pectoris, various cardiac dys-
rhythmias, and for idiopathic hypertrophic sub-
aortic stenosis. They also have been used for di-
verse conditions such as migraine and anxiety
states and as supportive therapy during withdrawal
of alcohol and addictive drugs.
Because these agents are so commonly used, it is
timely to evaluate their effects on renal function.
There appear to be three principal mechanisms by
which the beta blockers could influence the kidney:
first, by producing hemodynamic changes in the
systemic circulation; second, by acting on the re-
nin-angiotensin-aldosterone system; and third, by
possibly acting within the kidney to directly influ-
ence renal function. A listing of factors that may be
involved in mediating beta-blocker effects on the
kidney is given in Table 1. The decreases in system-
ic blood pressure and in cardiac output that are pro-
duced by most of these agents, together with the
variable increases in total peripheral vascular resist-
ance that can accompany these changes, probably
have an effect on renal function. Indeed, on the
basis of these changes, we could predict that beta-
blocker treatment would produce a reduction in
renal function. But perhaps changes in sodium and
water balance, and particularly the decreases in ac-
tivity of the renin aldosterone axis that are normally
induced by beta blockade, tend to modify altera-
tions in renal function that might be produced by
systemic circulatory factors. The beta-blocking
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drugs also have an action in the central nervous sys-
tem and can influence the activity of the peripheral
sympathetic nervous system [1]. But, whether beta-
blocker-induced changes in sympathetic drive to
the kidney can influence renal function is not
known. Indeed, the importance of these factors re-
mains somewhat speculative, particularly in view of
the varying and contradictory reports from investi-
gators who have studied the effects of the beta
blockers on circulatory and renal function. There is
also disagreement as to whether these changes in
renal function have long-term harmful effects. And
in particular, the action of the beta blockers on the
intrarenal release of renin, and the possible impor-
tance of alterations in activity of the renin-angioten-
sin system in mediating changes in blood pressure
and in circulatory hemodynamics, has become a
matter of considerable controversy.
Pharmacologic characteristics of beta blockers
Inconsistencies between different reports of the
effects of beta-adrenoceptor blocking drugs are at
least partly dependent on differences between the
pharmacologic characteristics of the various agents
within this group. Therefore, we will consider brief-
ly some of the properties of this class of drugs so as
better to understand their actions under various
clinical and physiologic circumstances.
The first agent found to exhibit specific blockade
of beta adrenergic receptors was dichloroisopro-
terenol [2]. But pronetholol, which was first avail-
able in 1962 [3], and propranolol, which followed 2
years later [4], were the first beta blockers to be
freely available for therapeutic and investigational
use. Normally, the beta-adrenoceptor antagonists
have a suppressive effect on the cardiovascular sys-
tem, reducing resting heart rate, cardiac output, and
contractility, and lowering blood pressure. The beta
blockers also inhibit certain metabolic processes.
Thus, the increases in plasma free fatty acid and
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Table 1. Factors possibly implicated in mediating effects on renal
function of beta-adrenoceptor blockade
Cardiac output
Systemic blood pressure
Total peripheral resistance
Renal blood flow
Renal vascular resistance
Sympathetic nervous system
Renin-angiotensin-aldosterone system
Water and sodium balance
blood glucose concentrations, and the fall in serum
potassium concentration, which are caused by sym-
pathetic stimulation or by other sympathomimetic
factors, are prevented by these agents [5, 6]. The
therapeutic uses of the beta blockers are largely re-
lated to their effects on the cardiovascular system.
Because of their action in reducing cardiac work
and myocardial oxygen requirements during exer-
cise, these drugs are of value in treating angina pee-
tons [7]. Similarly, they are effective in the treat-
ment of several forms of cardiac arrhythmias, espe-
cially those related to digitalis toxicity and to
valvular and ischemic heart disease [8, 9].
The beta-adrenoceptor blockers all possess a
competitive afilnity for beta receptors, but their ef-
fects on these receptors vary. Despite their designa-
tion as antagonists, a number of these agents exhibit
partial agonist properties (intrinsic sympa-
thomimetic activity). For example, in the isolated
cat's heart preparation, the intrinisic sympa-
thomimetic activity of pindolol was found to be 56%
that of the reference beta-agonist isoproterenol,
whereas that of practolol was 35%, oxprenolol 29%,
and alprenolol 16% [10]. Propranolol has virtually
no agonist properties [Ii]. In man or in the intact
animal, the degree of agonist activity exhibited by
the beta blockers depends to a large extent on the
level of adrenergic drive: thus, whereas pindolol in-
creases heart rate and plasma renin activity in the
resting animal, it has an inhibitory effect when given
to animals already receiving sympathomimetic
agents [6]. The presence or absence of sympa-
thomimetic activity in beta blockers does not ap-
pear to influence their antihypertensive properties.
There appear to be two types of receptors that
can mediate beta adrenergic activity: beta-I and
beta-2 [12]. This differentiation is both functional
and anatomical, for beta-i receptors are associated
predominantly with the heart and with lipid-con-
taining tissue, whereas beta-2 receptors are con-
cerned with peripheral vasodilation (chiefly in
muscle tissue) and bronchodilation. Although many
beta blockers are nonspecific, having affinity both
for beta-i and beta-2 receptors, agents such as prac-
tolol, metoprolol, atenolol, and acebutolol appear
to react primarily with beta-i receptors. There do
not appear to be any consistent differences between
selective and nonselective beta blockers in their ef-
fects on systemic hemodynamics. Each beta-adre-
noceptor antagonist has two optically active stere-
oisomers: the d and 1 forms. Although beta receptor
blockade is confined to the 1-isomers, both the d and
the 1 forms possess local anesthetic activity [13].
These drugs also have a quinidine-like action on the
heart, reducing the rate of rise and the conduction
velocity of action potentials and prolonging their
depolarization phase [14]. These properties, also
sometimes called membrane stabilizing properties,
do not appear to contribute, however, to the known
clinical effects of these drugs.
Renal mechanisms in determining beta-blocker
pharmacokinetics
Important differentiations between the various
beta-blocker agents are related to their pharma-
cokinetic properties. In this context, renal function
appears to a be critical for several of these agents.
Although almost all beta blockers are well absorbed
from the small bowel, there is considerable varia-
tion in the degree to which they are subjected to
hepatic extraction from the portal circulation. Thus,
propranolol is subjected to considerable hepatic
metabolism (first pass clearance) immediately fol-
lowing absorption, but for agents such as pindolol
or practolol this mechanism is less important. In
general, agents such as propranolol or alprenolol,
which have fairly high degrees of lipid solubility,
are subjected to a greater measure of hepatic metab-
olism than are less lipophilic agents such as me-
toprolol or atenolol [15]. The main pathway of elim-
ination for these latter agents is through renal excre-
tion; in the urine, approximately 40% of an oral
dose of either of these drugs can be recovered un-
changed, whereas propranolol or alprenolol occur
almost entirely in their metabolized forms [15].
Thus, pharmacokinetic properties such as elimina-
tion half-life of a number of beta blockers are close-
ly dependent on the state of renal function; creati-
nine clearance correlates directly with the renal
clearance of such drugs [16] and inversely with their
plasma half-life values [17]. For example, the
plasma half-life of sotolol averages 42 hours in pa-
tients with advanced renal failure, but is only 5
hours in normal subjects [18]. Beta-blockers with a
low order of binding to plasma proteins can ef-
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fectively be extracted from the circulation by hemo-
dialysis [16].
Beta blockers and renal function
Most investigators have reported that the admin-
istration of beta-blocking agents to human subjects
produces little or no alteration in renal function.
Thus, no significant changes in serum creatinine or
blood urea nitrogen concentrations have been re-
ported with propranolol [19, 20], pindolol [21], ace-
butolol [22], or metoprolol [23] when these agents
have been given for the treatment of hypertension.
In other more detailed studies designed to exam-
ine prospectively the effects of beta-blocking agents
on renal function, similar conclusions have been
reached. Thus, during acute administrations of pro-
pranolol in man, Schirmeister et a! [24] found that
GFR was reduced only minimally, although there
was a concomitant decrease of 10 to 15% in renal
blood flow. In a dog model, Winer, Chokski, and
Walkenhorst [25] also found that acute infusions of
propranolol did not alter creatinine clearance.
There was no alteration in para-aminohippuric acid
(PAH) clearance when the drug was infused in this
study. In an investigation performed by Ibsen and
Sederberg-Olsen [26] in 20 patients with essential
hypertension, the effect of propranolol on GFR was
measured as the clearance of radiolabeled sodium
chromate-ethylene diaminotetraacetic acid (51Cr-
EDTA). In a subgroup of 12 patients in whom gb-
merular filtration was measured after 2 to 3 months,
and again after 4 to 5 months, there was an average
reduction of 13% on each occasion. In a further 8-
patient subgroup, it was shown, however, that the
reduction in GFR produced by 4 months of propran-
olol treatment was completely reversed within 2
months of discontinuing the medication. Parallelling
these reductions in GFR, the patients experienced
significant decreases in mean blood pressure, which
also were reversed after cessation of therapy. Thus,
it was concluded that the reductions in GFR during
treatment were simply a reflection of the proprano-
lol-induced decreases in blood pressure, and pre-
sumably were mediated through changes in renal
perfusion pressure.
In a study by Pederson [27] in which alprenolol
was administered for periods of one month, patients
were divided into two groups: a younger group
composed of patients with mild hypertension, and
an older group comprising patients with moderate
hypertension. In neither group were there signifi-
cant changes in GFR (measured by '25iothalamate
clearance) or in renal plasma flow (measured as
hippuran clearance). There was, however, a greater
blood pressure reduction in the younger patients
than there was in the older group. Moreover, the
younger patients experienced a significant decrease
in renal vascular resistance, whereas no such
change occurred with the older, more severly hy-
pertensive group. This finding suggested that the
chronicity of hypertension might be important in
mediating the renal response to beta-blocker treat-
ment, perhaps reflecting progressive structural
changes together with decreased responsiveness of
the renal vasculature as the hypertensive disease
advances. Although there were no significant
changes in renal function in this study, it could be
inferred that older or more severely hypertensive
patients might be more susceptible to treatment-in-
duced changes in renal function.
In a similar study by Dreslinski et al [28], in
which 11 patients were treated with acebutobol for 4
weeks, creatinine clearance was found to remain
constant. This study might not have provided an
adequate test of renal function during beta block-
ade, however, for there were no significant changes
in mean arterial blood pressure or in the total pe-
ripheral resistance index. But despite this lack of
systemic hemodynamic changes, there was a signif-
icant reduction of 16% in renal blood flow. This
study, therefore, raises the possibility that there
might be some selective action of beta blockers
within the renal vasculature that could produce a
degree of vasoconstriction that is greater than that
observed in the systemic circulation. But in a more
recent experience, Hollenberg et al [29] found that
nadolol, apparently in contrast to other beta block-
ers, increased radioxenon-measured renal blood
flow by 26%, perhaps secondary to the drug's re-
versal of angiotensin-mediated intrarenal vaso-
constriction (see below).
Recently, Bauer and Brooks [30] have reported
the effects of administering propranolol to eight
young normal volunteers during a 4-week period.
As in most previous studies, these investigators al-
so found that beta-blocker treatment did not signifi-
cantly alter either regular or true creatinine clear-
ance. Propranobol produced, however, significant
decreases in GFR as measured by inulin clearance,
and there was also a significant reduction in renal
blood flow as measured by PAH clearance. In three
patients receiving propranolol in a high dose (320
mg daily) for 1 month, there were no changes in
plasma creatinine concentrations, although endoge-
nous creatinine clearance did appear to fall. This
small patient subgroup also experienced big de-
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dines in inulin clearance. These findings emphasize
that serum creatinine is not as reliable a measure of
renal function as is creatinine clearance during beta-
blocker treatment; and furthermore, they suggest
that creatinine clearance is not as sensitive as is in-
ulin clearance in quantifying changes in GFR. It is
of interest that Bufano and Piacentini [31], who also
are among the comparatively few investigators to
report substantial decreases in renal function during
beta blockade, similarly used inulin clearance as
their measure of GFR. The additional finding by
Bauer and Brooks [30] of an inverse correlation be-
tween inulin clearance and the fractional excertion
of creatinine helps explain this discrepancy, for it
indicates that there may be an increase in creatinine
secretion by the nephron during beta-blocker ad-
ministration. A disturbing finding in this study was
that GFR was still suppressed even 2 months after
discontinuation of propranolol treatment, despite
the normalization of renal blood flow and blood
pressure. This suggests some direct form of beta-
blocker-induced damage, perhaps mediated by in-
trarenal ischemic changes similar to those evoked
to explain long-term reductions of renal function
previously reported after beta-blocker administra-
tion in the dog [32].
The mechanisms by which beta-blocking agents
may influence renal function are not clear. Despite
occasional instances [28] where the intrarenal ef-
fects of beta blockade do not appear to reflect
changes in systemic hemodynamics, there is little
evidence that these agents produce meaningful di-
rect effects within the renal vasculature or in the
nephron. The clearest impact of beta blockers with-
in the kidney is related to their effects on renin se-
cretion; the resulting changes in the regulation of
hemodynamic and volume factors by the renin-an-
giotensin-aldosterone system might play a key role
in determining the renal effects of beta blockade,
and are detailed later.
Systemic factors
As discussed earlier, it has been generally as-
sumed that the effects of beta adrenoceptor block-
ers on the kidney are mediated largely through the
changes that these agents cause in systemic hemo-
dynamics. This role of circulatory factors in influ-
encing renal function during beta blockade has been
emphasized by the finding of Nies, McNeil and
Schrier [33] that the infusion of propranolol into just
one renal artery in the dog produced functional
changes that were equally apparent in both kidneys.
Thus, it seemed likely that the concurrent changes
in systemic hemodynamics—chiefly a reduction in
blood pressure—that occured during the adminis-
tration of propranolol were responsible for altering
renal function.
The most frequent use of the beta-blocking drugs
in the clinical setting is for the reduction of blood
pressure in hypertensive patients [34, 35]. There is
some controversy concerning the mechanism by
which the blood pressure is reduced, especially as
the beta blockers have effects on the renin-angio-
tensin system, cardiac output, the central nervous
system, and perhaps even on baroreceptor mecha-
nisms. The majority of beta-blocking agents used in
clinical practice have a suppressive effect on car-
diac output [36-38]. This effect is largely dependent
on a decrease in heart rate; its amplitude is related
to the degree of intrinsic sympathomimetic activity
of the blockers: agents possessing partial agonist
properties produce lesser reductions in heart rate
and cardiac output than do agents such as proprano-
lol [39, 40].
Although a reduction in cardiac output is a com-
mon finding with beta-blocker treatment, changes in
other hemodynamic parameters vary. Initially, total
peripheral resistance frequently increases, and then
may or may not fall. This variability in the effect of
the beta blockers on peripheral resistance is due to
the multiple mechanisms, some vasodilator and oth-
ers vasoconstrictor, that can be evoked by these
drugs. In general, the action of the beta blockers on
the renin-angiotensin system or on the central or pe-
ripheral nervous sytems would be expected to
lower peripheral resistance; whereas vasoconstric-
tor effects could result from reflex-mediated in-
creases in sympathetic drive secondary to cardiac
output reduction, or might reflect the blockade of
the vasodilatory peripheral vascular beta receptors
by the drug. Recent in vitro studies also point out
the possibility of direct alpha-stimulatory effects of
beta-blocking agents that might also be acutely
vasopressor [41]. Ultimately, it is the resolution be-
tween these conflicting actions that determines the
final state of peripheral resistance. And because the
effects on cardiac output of agents such as propran-
olol are fairly constant, it is the eventual degree of
peripheral resistance that determines whether or
not a fall in blood pressure will occur in any particu-
lar patient [42]. The mechanism by which these he-
modynamic changes may alter renal function are
not clear. Although it has generally been presumed
that changes in renal perfusion resulting from the
hemodynamic effects of the beta blockers are
largely responsible, it is also possible that the van-
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ous actions of these drugs described in the peripher-
al circulation might also occur within the renal vas-
culature.
Volume and electrolyte effect of beta-blocker treatment
A well-recognized characteristic of patients with
essential hypertension is that they excrete a sodium
load more rapidly than do normal subjects [43, 44].
The mechanism by which this rapid natriuresis oc-
curs is not well understood, and there is conflicting
evidence concerning the alterations in renal func-
tion induced by the sodium load. Thus, Kraus et al
[45] and Lowenstein et al [46] have shown that the
sodium challenge increases both renal plasma flow
and GFR, thereby facilitating rapid elimination of
the sodium load. Other authors [47], however, were
not able to reproduce these findings; and in a more
recent study, Pedersen [48] found that renal plasma
flow and GFR actually decreased when sodium in-
fusions were given to patients with essential hyper-
tension. But in the same study, pretreatment of the
patients with propranolol prevented these renal
functional changes in response to sodium loading.
Consistent with this, patients receiving propranolol
had significantly lower urinary sodium excretion
rates than did untreated hypertensive patients when
subjected to sodium infusions, and now appeared to
handle the sodium load in the same fashion as nor-
motensive volunteers. In both the studies of Ped-
ersen [48] and of Kraus et al [45], the administration
of propranolol produced significant reductions in
systemic blood pressure, and it was assumed that
the resulting decrease in renal perfusion played a
key role in "normalizing" the renal functional re-
sponse to sodium loading.
Changes in sodium and water status induced by
beta-blocking agents might be of importance in in-
fluencing renal function during treatment. Table 2
lists a selection of studies with beta-blocking agents
in hypertensive patients for whom parameters of
plasma volume status were measured. In general,
the administration of beta-blocking agents as single
therapy does not appear to produce major altera-
tions in overall volume balance, although in one
study (not included in the table) a change in the cir-
cadian pattern of sodium excretion was observed
during propranolol treatment [49]. During periods
of treatment of up to 5 months, measurements of
plasma volume have generally not deviated sub-
stantially from control values. Although there was a
tendency for beta-blocker monotherapy to produce
a very slight increase in average body weight, only
in the study of Drayer et al [50] did this form of
treatment produce a substantial weight gain. It is of
particular interest, however, that the concurrent ad-
ministration of a diuretic apparently produced a
Table 2. Change in volume status during beta-adrenoceptor blockade in hypertensive patientsa
No. of Months of Change in plasma
Study patients treatment volume
Bravo et al [51] 20 1 6%b
Dreslinski et al [28] 11 1 None
Ibsen and Sederberg-Olsen [26] 11 2 to 5 None
Krauss et al [45] 10 0.5 None
Sederberg-Olsen and Ibsen [53] 10 1 None (but 4%
increase in ECF volume)
Tarazi eta! [54] 8
10
<9
>12
—11%
—7%
Alhenc-Gelas et al [22]c 20 1.5
Avg. change in body wt. kg
0.0
Bühler eta! [57] 47 Ito 12 +0.3
Drayeret a! [93] 50 Ito 12 +0.4
Drayeretal[50] 11 2 +2.3
Hollifield eta! [96] 40 1.5 +0.9 (low dose)
+0.2 (high dose)
Jaegereta![125] 12
12
1
2
0.0
+l.0
Karlberg et a! [126] 27
27
2
2
+0.118b
Weber eta! [60] 59
20
Ito 12
ltol2
+ 1.3
14b
Weber et al[23]' 20
20
1
1
+0.413b
a Propranolol was used except where otherwise indicated.
b Patients were concurrently receiving diuretic.
Acebutolol was used.
ci Metoprolol was used.
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tendency for greater weight gain in almost all cases,
and also was associated with the single instance [51]
of an increase in plasma volume. Presumably, this
heightened tendency to volume accumulation when
beta-blocking drugs are superimposed on diuretic
therapy reflects an accentuation of the com-
pensatory hemodynamic changes induced by the
initial diuretic-induced volume depletion. Thus, the
reduction in cardiac output that beta blockers nor-
mally produce, when superimposed on a state of
relative volume depletion, might well provoke a
mild degree of functional "heart failure," leading to
sodium and water accumulation. This might be of
particular importance in patients whose diuretic
therapy has been of only short duration, for cardiac
output may actually be decreased by diuretic thera-
py itself during the early phases of treatment [52].
Support for this idea comes from the study of Se-
derberg-Olsen and Ibsen [53], who found a tenden-
cy for an increase in total extracellular fluid volume
during beta blockade even though plasma volume
remained at pretreatment levels. This finding also
explains the slight weight increase during beta-
blocking treatment even though circulating plasma
volume remains constant or even decreases [54,
55]. It has also been noted that beta blockers may
produce an acute sequestration of plasma volume
independent of systemic hemodynamic changes
[56], but this phenomenon does not appear to be im-
portant during long-term treatment.
This finding that the beta-blocking agents do not,
in general, produce volume retention is of interest,
for sodium accumulation is common with most oth-
er forms of nondiuretic antihypertensive therapy.
These differing effects of volume status cannot
readily be explained by differences in systemic he-
modynamic patterns, for the beta blockers are usu-
ally as effective as other agents are in lowering
blood pressure, and tend to produce even greater
reductions in cardiac output. One important dif-
ferentiation, however, may be related to the pow-
erful inhibitory effect on the renin-angiotensin sys-
tem exhibited by many beta-blocking agents. This,
in turn, would be expected to produce decreases in
aldosterone secretion from the adrenal cortex,
thereby diminishing sodium and water-retaining
mineralocorticoid activity in the distal nephron;
thus, this action could be expected to compensate
for the reduced renal blood flow that results from
the antihypertensive beta-blocker effect and which
decreases peritubular blood flow and enhances
proximal sodium reabsorption [33].
When used as single agents in clinical practice,
the majority of beta-blocking agents do not produce
significant changes in serum concentrations of elec-
trolytes. Probably the most consistent tendency ob-
served with these agents is a modest increase in
serum potassium concentrations [23, 57]. It is prob-
able that the decrease in aldosterone production
(see below) that occurs secondary to the antirenin
action of most beta blockers is responsible for this
change, for it could be predicted that renal con-
servation of potassium would occur during de-
creased aldosterone activity [58]. Because beta-ad-
renergic stimulation, perhaps by direct beta-recep-
tor activation, might inhibit sodium reabsorption in
the proximal nephron [59], it could perhaps be pre-
dicted that beta-blockade would increase proximal
sodium reabsorption and thereby decrease sodium
delivery to the distal tubule, a condition that also
would result in some degree of potassium retention
[58]. This tendency for a potassium-raising effect of
beta blockers has been considered to be of value
when these agents are administered with diuretics,
for it should help minimize the hypokalemia that
would otherwise result. But, in two studies in which
patients were pretreated with a diuretic, the addi-
tion of propranolol appeared actually to worsen the
hypokalemia [60, 61]. This finding could not be ex-
plained by changes in aldosterone excretion, and it
was therefore speculated that the combination
treatment increased sodium delivery to the distal tu-
bule with a consequent loss of potassium. Studies
performed in animal models have indicated the pos-
sibility that changes in potassium concentrations al-
so may occur secondary to extrarenal mechanisms.
It has been shown that beta-receptor stimulation
with isoproterenolol or epinephrine reduces plasma
potassium, and that this effect can be at least partly
blocked by beta blockade [12, 62]. Whether beta
blockers administered in the unstimulated state ac-
tually can cause an increase in plasma potassium,
perhaps by affecting the postulated beta-receptor
control of intracellular potassium storage in tissues
such as the liver [63], muscle [64], or heart [65] is
not known.
Beta-blocker effects on renin release
Some of the major actions of the beta-adrenocep-
tor blocking agents on renal function are mediated
through their effects on the renin and aldosterone
systems. Thus, by influencing renin secretion, these
agents can alter the production of angiotensin II
(All), which in turn will effect systemic blood pres-
sure and the flow of blood to the kidney. Moreover,
changes will occur in aldosterone secretion from
the adrenal cortex, which may then result in altered
sodium, potassium, and water regulation in the
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distal renal tubule. Thus, the action of the beta-
blocking agents to the renin hormonal system ap-
pears to be critical in mediating their effects on re-
nal function.
Although renal extracts were previously shown
to exhibit pressor properties [66], it was not until
Goldblatt performed his classic renovascular hyper-
tension experiments [67] that the importance of the
renin system in the regulation of blood pressure and
in the pathogenesis of hypertension started to be ap-
preciated. Mechanisms by which the renin-aldoste-
rone axis is thought to be involved in the regulation
of blood pressure are shown in Fig. 1. Renin is
thought primarily to be a rate-limiting enzyme that
acts by cleaving the decapeptide molecule, angio-
tensin I, from a large glycoprotein substrate, angio-
tensinogen. Angiotensin I itself has little physiolog-
ic action, but is acted upon by a converting enzyme
that produces the octapeptide All. Although it has
several cardiovascular effects, the two main actions
of All are shown in Fig. 1. First, it works directly
on small arteries and arterioles, exhibiting a potent
vasoconstrictor effect [68]. This action is believed
to be important in the minute-to-minute modulation
of blood pressure by the renin-angiotensin system.
The second major action of All is to stimulate the
secretion of aldosterone from the adrenal cortex
[69]. This more chronic effect is dependent on the
sodium and water retaining action of aldosterone in
the distal renal tubule, which in turn expands the
circulating plasma volume.
The control of renin secretion from the kidney is
clearly important, because this is a major determi-
nant of the regulation of blood pressure by the re-
nin-aldosterone axis. There appear to be three main
influences on renin release. First, it is sensitive to
changes in intrarenal arterial blood pressure: a per-
ception by the intrarenal baroreceptor (presumably
located within the renin-containing juxtaglomerular
cells of the afferent arteriole) of reduced pressure
results in increased renin secretion, whereas a rise
in pressure decreases renin release [70]. Second, re-
nm release appears closely dependent on the state
of sodium balance: sodium depletion increases, and
sodium (or volume) expansion decreases renin se-
cretion [71]. And third, the role of adrenergic fac-
tors is also important, for activation of the sympa-
thetic nervous system or increases in circulating
catecholamines stimulate the release of renin from
the kidney [72].
The effects of beta-adrenoceptor blocking agents
in influencing renin release and in altering the cir-
culatory and renal actions of the renin-angiotensin
Reniri substrate
(A ngiotensi n ogen(
•*— Rerun—————
Angiotensin I
Angiotensin II
1 Aldosterone
Sodium and water ——
retention
W Blood pressure
Fig. 1. Schema of the renin-angiotensin-aldosterone system as
described in the text. Dotted lines indicate negative feed-back
regulation of renin secretion.
system have been clarified by studies in animal
models and in man. For example, propranolol has
been shown to prevent the increase in renin secre-
tion caused by a variety of stimuli, including circu-
lating epinephrine or norepinephrine [73], medulla
oblongata stimulation [74], and the assumption of
upright posture [75]. To characterize more specifi-
cally mechanisms by which propranolol exhibits its
inhibitory effects on renin release, a series of stud-
ies were performed in the New Zealand white rabbit
[76]. In this species it is possible to use the con-
scious animal, thereby avoiding the inadvertent al-
terations in renal, hormonal, or circulatory parame-
ters that can be produced by general anesthetic
agents. Moreover, methods have been established
that circumvent changes in these parameters due to
blood sampling or other stimuli [77]. The effects of
acute intravenous administration of propranolol in
this model have been detailed previously [76] and
are summarized in Fig. 2. Plasma concentrations of
the drug are high by 30 mm, and then decline loga-
rithmically during the next 2 hours. These plasma
concentrations are related to the beta-blocking ef-
fectiveness of the drug, for they parallel its ability to
block isoproterenol-induced tachycardia. Of partic-
ular relevance, the reduction in plasma renin activi-
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Fig. 2. Effects in conscious New Zealand white rabbits of pro-
pranolol, given as a single i.v. bolus (1 mg/kg) at the start of
each study (0 mi, on: plasma propranolol concentration (N =
6); isoproterenol dose ratio, defined as the infusion rate of
isoproterenol required to raise heart rate by 40 beats/mm during
the study as compared to that required prior to propranolol (N =
4);and on plasma renin activity, mean blood pressure, and heart
rate (N = 10).
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Fig. 3. Effects of infusions of different beta-blocking agents, giv-
en in comparable clinical doses, on mean blood pressure and
plasma renin activity in the conscious rabbit (N = 6 in each
case).
ty appears dependent on the degree of beta block-
ade; the renin disappears from the plasma during
the first 30 mm after administration of the drug, and
then starts to rise again as the plasma concentra-
tions of propranolol decrease. It is of interest that
the changes in both blood pressure and heart rate
appear related to those in plasma renin activity; in-
deed, there were significant correlations between
the changes in renin and those in either mean blood
pressure (r = 0.76) or heart rate (r = 0.56).
To characterize in greater detail the effects of
beta blockers on renin release, the investigators ad-
ministered continuous infusions of several of these
agents to conscious rabbits during 6-hour periods
[12]. The results of these studies are summarized in
Fig. 3, and allow some conclusions concerning the
nature of the beta-adrenoceptor regulation of renin
release. First, the nonbeta-blocking d-isomer of
propranolol had no effect on plasma renin activity.
This contrasted to the powerful suppressive action
of the racemic (dl). mixture, thus making it highly
likely that renin release is mediated by an effect at
the beta-adrenoceptor. A second finding was that
the cardioselective (beta1) blocker, practolol, did
not significantly alter plasma renin, whereas H351
25, an agent possessing some degree of beta2 selec-
tivity [78], produced a significant reduction. Where-
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as this finding suggested that the receptor mediating
renin release might be of the beta2 subtype, other
studies have produced conflicting evidence con-
cerning the primacy of either beta1 or beta2 recep-
tors in this role [79, 80]. Although metoprolol pro-
duced a reduction in plasma renin activity, it should
be remembered that this agent, as with many other
apparently cardioselective agents, still possesses a
measurable degree of beta2-blocking activity [81].
A third finding was that pindolol produced a dra-
matic increase in plasma renin activity. This was of
particular interest, for this rise in plasma renin was
accompanied by an unequivocal fall in blood pres-
sure, a finding that appeared to eliminate any role
for renin suppression in the blood pressure-lower-
ing action of pindolol. To examine further this phe-
nomenon, the investigators infused propranolol into
rabbits during 6-hour studies; and during the second
3-hour portions of these experiments, they superim-
posed pindolol infusions [12]. Interestingly, plasma
renin activity, which decreased significantly with
propranolol alone, rose back to control when the
pindolol was added. The antihypertensive action of
the propranolol was sustained, however, for no fur-
ther changes in blood pressure occurred when the
pindolol was added. It is probable that the renin-
stimulating action of pindolol is due to its known
powerful intrinsic sympathomimetic properties
[10], for despite its stimulatory effect in the resting
rabbit, it was able to significantly attenuate the re-
nm-increasing action of isoproterenol [12].
It is also possible, however, that the increase in
renin was mediated by activation of a baroreceptor
mechanism secondary to the pindolol-induced fall
in blood pressure. But in further studies with pindo-
lol [82], in which the use of low doses avoided any
measurable changes in systemic and renal hemo-
dynamic or functional parameters in the rabbit, in-
creases in renin secretion occurred only when pin-
dolol was administered directly into the renal ar-
tery. Furthermore, there was a close correlation
between the renin secretion rate and renal vein
plasma pindolol concentrations, further indicating
that this beta blocker affected renin release by a di-
rect pharmacologic action within the kidney. There
is also in vitro evidence supporting the role of intra-
renal beta receptors in mediating the action of beta-
blocking drugs on renin release. Changes in renin
release from renal cell suspension preparations [83]
or from kidney slices [84, 85] can predictably be in-
creased by beta-agonist compounds and decreased
by beta-antagonist compounds. Moreover, it is
known that the juxtaglomerular cells of the kidney,
in which renin is stored, are richly endowed with
beta-adrenergic receptors [86]. And in physiologic
studies in the sodium-depleted dog, Johnson et al
[87] found that the inhibitory effect of propranolol
on renin release was primarily dependent on its ac-
tion on renal juxtaglomerular cells.
Evidence that beta-adrenoceptor blocking agents
work on receptors within the kidney, together with
the known relationship between beta receptors and
the cell membrane adenyl cyclase system [88], has
allowed speculation that the beta blockers may in-
fluence production of renal cyclic AMP. To exam-
ine this possibility, studies were carried out in hu-
man hypoparathyroid subjects so as to exclude the
intrarenal production of cyclic AMP by parathyroid
hormone, normally the chief source of this com-
pound in the urine, and thereby amplify any
changes in cyclic AMP excretion related to beta ad-
renergic mechanisms [89]. When these patients
were subjected to severe dietary sodium restriction,
significant increases occurred both in plasma renin
activity and in the fractional excretion of cyclic
AMP; however, when propranolol treatment was
superimposed, both parameters tended to return to-
ward their baseline values. Moreover, during the
study, there was a significant correlation between
the induced changes in plasma renin and in urinary
cyclic AMP, again supporting the idea that the re-
nm-release mechanisms were at least partly depen-
dent on adenyl cyclase-mediated beta-adrenoceptor
activity.
Beta blockers and renin in clinical situations
The effects of the beta-adrenoceptor blocking
agents on the renin system in clinical practice are
similar to those observed in animal studies. Thus,
the majority of beta-blocking drugs produce signifi-
cant decreases in plasma renin activity, although
agents such as pindolol may exhibit variable effects,
including increases [90, 91], on renin levels. Most
beta-blocking agents also have an inhibitory effect
of aldosterone [57, 92], which is probably second-
ary to the induced suppression of the renin-angio-
tensin system [69, 93].
There are various ways in which the intrarenal
renin-lowering effect of the beta blockers might im-
pact on renal function. Despite a continuing con-
troversy [94], there is evidence that the suppression
of renin release by the beta blockers, with a sub-
sequent decrease in the peripheral vasoconstriction
that is mediated by All, might play a role in the anti-
hypertensive action of these agents. Studies using
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the beta blockers themselves have been conflicting,
for there has been a general lack of agreement as to
whether the antirenin action of the beta blockers
correlates with their antihypertensive actions [57,
95, 96]. And again, there has been a lack of agree-
ment as to whether beta blockers work optimally in
patients with high renin values in whom it has been
theorized that the renin system itself is a major fac-
tor in sustaining the hypertension [97]. Although the
importance of renin blockade seems to be well es-
tablished in more extreme high renin states such as
malignant hypertension [98], and certain forms of
advanced renal insufficiency [99], the situation in
mild to moderate essential hypertension has been
confused by the variability between methods used
for measuring renin and for subclassifying patients
into high, normal, or low renin subgroups. Perhaps
the best evidence for a role of the renin axis in sus-
taining high blood pressure, and the potential im-
portance of blocking this axis in optimally treating
hypertension, comes from studies using agents that
specifically interfere with the renin-angiotensin sys-
tem. In general, the blood-pressure-lowering ef-
fectiveness of saralasin, an agent that competitively
blocks the actions of All, has correlated closely
with renin activity in the pretreatment state [100,
101]. Similarly, blockade of the renin axis with in-
hibitors of the conversion of Alto All has also in-
dicated that this system plays at least a partial role
in sustaining the high blood pressure levels in a pro-
portion of hypertensive patients [102, 103]. But al-
though it could be inferred that the antirenin effects
of beta-blocking agents might participate in their
antihypertensive actions, the complexity of their
multiple pharmacologic effects in the circulation
and in the central nervous system makes direct evi-
dence very difficult to obtain.
Because All also has effects that influence renal
function and volume balance, it seems likely that
some modification of these actions might be pro-
duced by the inhibitory effects of the beta-blocking
drugs on renin release. In physiologic concentra-
tions, All tends to produce sodium retention
through a reduction in renal blood flow and GFR
[104], although in higher concentrations [105] or in
hypertensive patients [106] an opposite diuretic ac-
tion has been suggested. All also appears able to
alter the distribution of renal blood flow, for in con-
ditions of hypotension it selectively constricts the
capillaries of superficial glomeruli in the renal cor-
tex [107], thereby diverting blood flow to inner cor-
tical juxtamedullary glomeruli and facilitating urine
concentration and retention of sodium [108]. It
could be speculated that beta-blocker treatment, by
inhibiting the renin-angiotensin system, might pre-
vent or minimize this antidiuretic response of the
kidney to a fall in blood pressure, thus allowing the
antihypertensive action of the drug to occur without
concomitant volume retention.
Further, it has been conjectured that heightened
intrarenal activity of the renin-angiotensin system
might mediate the oliguric renal failure produced by
a variety of ischemic stimuli [109—111], and that the
antirenin action of the beta-blockers could thus pre-
vent or modify this syndrome. The presence within
the kidney of all components of the renin-angioten-
sin system [112] is consistent with a renin-initiated
response to ischemia, either through blood flow re-
distribution or by intense constriction of glomerular
arterioles. Recently, it was found that the increase
in renal blood flow produced by nadolol in man was
related temporally to its suppressive effect on the
renin axis [29]. And propranolol has been shown to
decrease the severity of acute renal failure in exper-
imentally induced ischemia in the rat [113, 114], and
to protect renal function during the ischemic phase
of kidney transplantation in the dog [115]. Further
confirmation, however, that the protective action o
beta-blockers on renal function is dependent on
their antirenin effects have not been conclusive;
specific blockers of the renin axis such as saralasin
or converting enzyme inhibitors have produced in-
consistent effects. Acute renal failure also has been
attributed to nonrenin-related mechanisms includ-
ing tubular obstruction secondary to swelling and
necrosis of epithelial cells [116], or damage to the
tubular membrane that allows excessive leak-back
of lumenal contents through the interstitial space
[117]. Although propranolol can influence cell mem-
brane activity [118] and cellular integrity [119] un-
der certain circumstances, these properties cannot
yet be linked to its protective effect in acute renal
failure.
Similarly, there is no direct information con-
cerning the effect of beta blockers on the possible
role of All in the homeo static regulation (autoregu-
lation) of renal blood flow [120]. Moreover, other
hormonal systems, including catecholamines and
prostaglandins, also influence these complex vascu-
lar functions and also may be involved in mediating
responses during treatment with beta-blocking
drugs. All additionally sustains volume expansion
by its stimulatory action on hypothalamic thirst
centers [121] and by enhancing secretion of anti-
diuretic hormone from the pituitary gland [122]. But
again, it is only possible to speculate that beta-
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blocking drugs might reverse these volume-related
actions of angiotensin.
An important component of the effects of beta-
blocking agents on renal function and fluid and elec-
trolyte balance is related to the suppression of a!-
dosterone that results from their antirenin effect.
The role of aldosterone suppression in mediating
the effects on potassium of beta blockers, and in
minimizing or eliminating the antidiuretic effects
that result from the antihypertensive actions of
these agents, has been discussed earlier. Suppres-
sion of aldosterone, however, might have impor-
tance beyond the reduction of its mineralocorticoid
effects in the distal renal tubule. In studies of the
blood-pressure-lowering properties of beta blockers
and other antihypertensive agents, it has been noted
that aldosterone levels were suppressed to a signifi-
cantly greater extent in patients responding to treat-
ment than they were in those whose blood pres-
sures remained high [93, 123]. Moreover, because
responders and nonresponders could not be dif-
ferentiated from each other on the basis of standard
clinical measures of sodium, potassium, or water
balance, it has been theorized that aldosterone may
determine the outcome of treatment by mechanisms
independent of volume regulation [93, 124]. The
possible role of direct peripheral vasoconstrictor
actions of aldosterone in sustaining blood pressure
and the possible importance of inhibition of aldoste-
rone in determining the hemodynamic and renal ef-
fects of the beta-blocking agents are presently being
studied.
Summary. Beta-adrenoceptor blockers do not
substantially alter renal function as measured by
blood urea nitrogen, serum creatinine, or endoge-
nous creatinine clearance. But there is evidence
that inulin clearance may be decreased even when
creatinine clearance is apparently normal, suggest-
ing that the latter parameter may not dependably
measure GFR during beta blockade, perhaps due to
increased tubular creatinine secretion. A reduction
in renal blood flow also can occur, but this is not a
consistent finding and does not appear to correlate
with changes in renal function. Unlike most other
nondiuretic antihypertensive agents, beta blockers
do not normally cause sodium and water retention.
Thus, measurable increases in plasma volume do
not occur even with long-term treatment, and body
weight appears to increase only when the beta
blockers are superimposed upon preexisting diuret-
ic treatment. The most demonstrable intrarenal ef-
fect of the majority of beta blockers is their suppres-
sion of renin release, which in turn decreases pro-
duction of All and aldosterone. Inhibition of the
mineralocorticoid hormone aldosterone may be a
key factor in minimizing volume retention during
treatment, whereas decreases in the peripheral
vasoconstrictor actions of All might play a part in
the antihypertensive effects of these agents.
Reprint requests to Dr. M. A. Weber, Hypertension Center,
Veterans Administration Medical Center, Long Beach, Calfor-
nia 90822, USA
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